\-\ Texto\\:\\ \ \(0\)\
\-\ patient\\ is\\ a\\ well\\ developed\\,\\ well\\ nourished\\.\\ bilateral\\ optic\\ nerve\\ head\\ edema\\ noted\\.\\ normal\\ visual\\ acuity\\,\\ eomi\\,\\ perrla\\,\\ and\\ all\\ other\\ cranial\\ nerves\\ showed\\ no\\ abnormality\\.\ \(0\)\
\-\ also\\ noted\\ on\\ mri\\ was\\ occipital\\ bone\\ marrow\\ replacement\\ and\\ enhancement\\ on\\ undersurface\\ along\\ with\\ lymphadenopathy\\ on\\ ct\\ making\\ diagnosis\\ of\\ lymphoma\\ likely\\.\\ biopsy\\ of\\ axial\\ lymph\\ nodes\\ and\\ extraconal\\ mass\\ showed\\ presence\\ of\\ b\\ cell\\ sll\\/cll\\ and\\ wbc\\ was\\ 47\\ with\\ differential\\ consistent\\ with\\ this\\ diagnosis\\.\ \(0\)\
\-\ due\\ to\\ slow\\ growth\\ and\\ lack\\ of\\ symptoms\\ at\\ this\\ time\\,\\ the\\ patient\\ may\\ elect\\ to\\ not\\ pursue\\ treatment\\ at\\ this\\ time\\.\\ \\ radiation\\ therapy\\ could\\ be\\ given\\ to\\ orbits\\ to\\ prevent\\ visual\\ problems\\ from\\ continued\\ growth\\ of\\ masses\\.\\ it\\ would\\ be\\ given\\ to\\ the\\ complete\\ orbits\\ at\\ dose\\ of\\ 20\\-25\\ gy\\ in\\ 2\\ gy\\ fractions\\.\\ this\\ will\\ invariably\\ lead\\ to\\ cataracts\\,\\ but\\ retinal\\ damage\\ and\\ xerophthalmia\\ would\\ be\\ unlikely\\ at\\ this\\ dose\\.\\ chemotherapy\\ can\\ also\\ be\\ considered\\ for\\ systemic\\ treatment\\.\ \(0\)\
\-\ mri\\:\\ extraconal\\ mass\\ along\\ the\\ roof\\ of\\ the\\ left\\ orbit\\,\\ 8mm\\ cc\\ x\\ 3\\.8cm\\ ap\\ x\\ 3\\.4cm\\ transverse\\,\\ indistinct\\ from\\ lacrimal\\ gland\\.\\ right\\ lacrimal\\ gland\\ also\\ enlarged\\ or\\ surrounded\\ by\\ mass\\.\ \(0\)\
\-\ b\\-cell\\ lymphoma\ \(1\)\
\-\ metastatic\\ tumors\\ \\(carcinomas\\ of\\ lung\\,\\ prostate\\,\\ gi\\,\\ renal\\,\\ skin\\,\\ \\(breast\\ in\\ female\\)\\)\\;\\ lacrimal\\ gland\\ lesions\\ \\(infiltrative\\ processes\\ and\\ epithelial\\ neoplasms\\)\\;\\ mesenchymal\\ tumors\\ \\(fibroma\\,\\ fibrosarcoma\\,\\ leiomyosarcoma\\,\\ fibrous\\ histiocytoma\\,\\ and\\ rhabdomyosarcoma\\ \\(most\\ common\\ orbit\\ tumor\\ in\\ children\\)\\)\\;\\ neurogenic\\ tumors\\ \\(neurofibroma\\,\\ schwannoma\\,\\ and\\ gliomas\\ and\\ meningiomas\\ of\\ the\\ optic\\ nerve\\)\\;\\ inflammations\\;\\ structural\\ lesions\\ \\(dermoid\\ cysts\\ and\\ mucoceles\\)\\;\\ vascular\\ neoplastic\\ lesions\\;\\ lymphoproliferative\\ lesions\\.\ \(0\)\
\-\ the\\ patient\\ was\\ diagnosed\\ with\\ pseudotumor\\ cerebri\\ 3\\ yrs\\ ago\\ and\\ presented\\ for\\ follow\\ up\\ with\\ opthalmology\\ with\\ no\\ complaints\\ or\\ specific\\ symptoms\\.\\ he\\ did\\ report\\ a\\ 10\\ lb\\ weight\\ loss\\ over\\ past\\ 18\\ mos\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ lacrimal\\:\\ 0\\.23570792501783827\ \(0\)\
\-\ gy\\:\\ 0\\.17953534436809993\ \(0\)\
\-\ extraconal\\:\\ 0\\.1743568299296214\ \(0\)\
\-\ and\\:\\ 0\\.16413038930612603\ \(0\)\
\-\ gland\\:\\ 0\\.16130848036628234\ \(0\)\
\-\ lesions\\:\\ 0\\.15205666472119783\ \(0\)\
\-\ orbits\\:\\ 0\\.1496479826792941\ \(0\)\
\-\ tumors\\:\\ 0\\.14603992731477364\ \(0\)\
\-\ dose\\:\\ 0\\.12362492200232426\ \(0\)\
\-\ orbit\\:\\ 0\\.12260466545421418\ \(0\)\
\-\ of\\:\\ 0\\.11657933853983683\ \(0\)\
\-\ optic\\:\\ 0\\.11395595329405027\ \(0\)\
\-\ this\\:\\ 0\\.11372187073968142\ \(0\)\
\-\ visual\\:\\ 0\\.11294679000560864\ \(0\)\
\-\ growth\\:\\ 0\\.10915874405283418\ \(0\)\
\-\ be\\:\\ 0\\.10740395546602766\ \(0\)\
\-\ xerophthalmia\\:\\ 0\\.10585360727551933\ \(0\)\
\-\ elect\\:\\ 0\\.10114877286674727\ \(0\)\
\-\ inflammations\\:\\ 0\\.10114877286674727\ \(0\)\
\-\ at\\:\\ 0\\.10000451476644842\ \(0\)\
\-\ to\\:\\ 0\\.09928552146495853\ \(0\)\
\-\ opthalmology\\:\\ 0\\.09781063972978464\ \(0\)\
\-\ fractions\\:\\ 0\\.09522138251054539\ \(0\)\
\-\ cataracts\\:\\ 0\\.09522138251054539\ \(0\)\
\-\ nerve\\:\\ 0\\.09444044456369212\ \(0\)\
\-\ would\\:\\ 0\\.09371060143484167\ \(0\)\
\-\ also\\:\\ 0\\.09340286157113005\ \(0\)\
\-\ mucoceles\\:\\ 0\\.09310580532101258\ \(0\)\
\-\ lymphoproliferative\\:\\ 0\\.09310580532101258\ \(0\)\
\-\ invariably\\:\\ 0\\.09131711029378618\ \(0\)\
\-\ given\\:\\ 0\\.09106518041539464\ \(0\)\
\-\ along\\:\\ 0\\.08869069468837427\ \(0\)\
\-\ showed\\:\\ 0\\.08817559613416326\ \(0\)\
\-\ pursue\\:\\ 0\\.08607247858586582\ \(0\)\
\-\ undersurface\\:\\ 0\\.08506283777527789\ \(0\)\
\-\ fibrosarcoma\\:\\ 0\\.08247358055603864\ \(0\)\
\-\ mos\\:\\ 0\\.08247358055603864\ \(0\)\
\-\ 8mm\\:\\ 0\\.08102124384468104\ \(0\)\
\-\ lb\\:\\ 0\\.0797306316939938\ \(0\)\
\-\ the\\:\\ 0\\.0792448590840924\ \(0\)\
\-\ lymphoma\\:\\ 0\\.07884152053910733\ \(0\)\
\-\ time\\:\\ 0\\.07846599294738858\ \(0\)\
\-\ with\\:\\ 0\\.0777659964445567\ \(0\)\
\-\ retinal\\:\\ 0\\.07751371281756735\ \(0\)\
\-\ mesenchymal\\:\\ 0\\.07751371281756735\ \(0\)\
\-\ meningiomas\\:\\ 0\\.07751371281756735\ \(0\)\
\-\ histiocytoma\\:\\ 0\\.07654619019983676\ \(0\)\
\-\ gliomas\\:\\ 0\\.07654619019983676\ \(0\)\
\-\ cerebri\\:\\ 0\\.07654619019983676\ \(0\)\
\-\ indistinct\\:\\ 0\\.07609109071756291\ \(0\)\
\-\ mass\\:\\ 0\\.07584943346442569\ \(0\)\
\-\ cell\\:\\ 0\\.07572845182171958\ \(0\)\
\-\ perrla\\:\\ 0\\.0752311752023168\ \(0\)\
\-\ leiomyosarcoma\\:\\ 0\\.07482399133964705\ \(0\)\
\-\ structural\\:\\ 0\\.07443061301030394\ \(0\)\
\-\ carcinomas\\:\\ 0\\.07405013468161385\ \(0\)\
\-\ acuity\\:\\ 0\\.07368173709258058\ \(0\)\
\-\ yrs\\:\\ 0\\.07368173709258058\ \(0\)\
\-\ symptoms\\:\\ 0\\.07243178663127846\ \(0\)\
\-\ eomi\\:\\ 0\\.07199711047048203\ \(0\)\
\-\ neurogenic\\:\\ 0\\.07199711047048203\ \(0\)\
\-\ roof\\:\\ 0\\.07138625630879084\ \(0\)\
\-\ epithelial\\:\\ 0\\.07109247987334133\ \(0\)\
\-\ noted\\:\\ 0\\.07018860228943763\ \(0\)\
\-\ was\\:\\ 0\\.06920451816049643\ \(0\)\
\-\ pseudotumor\\:\\ 0\\.06873764576631833\ \(0\)\
\-\ diagnosis\\:\\ 0\\.06862575336001825\ \(0\)\
\-\ surrounded\\:\\ 0\\.06804812317182822\ \(0\)\
\-\ mri\\:\\ 0\\.06795303672828064\ \(0\)\
\-\ nourished\\:\\ 0\\.06782709650065233\ \(0\)\
\-\ infiltrative\\:\\ 0\\.06782709650065233\ \(0\)\
\-\ rhabdomyosarcoma\\:\\ 0\\.06698282973948706\ \(0\)\
\-\ fibroma\\:\\ 0\\.06658266769209499\ \(0\)\
\-\ making\\:\\ 0\\.06619584689295878\ \(0\)\
\-\ neurofibroma\\:\\ 0\\.06545886595258897\ \(0\)\
\-\ processes\\:\\ 0\\.06510721633287014\ \(0\)\
\-\ patient\\:\\ 0\\.06458569923609801\ \(0\)\
\-\ damage\\:\\ 0\\.06443435832460248\ \(0\)\
\-\ cc\\:\\ 0\\.0641120167803905\ \(0\)\
\-\ prostate\\:\\ 0\\.0641120167803905\ \(0\)\
\-\ well\\:\\ 0\\.06409988888641142\ \(0\)\
\-\ slow\\:\\ 0\\.06379838824533\ \(0\)\
\-\ treatment\\:\\ 0\\.06306044498806858\ \(0\)\
\-\ nerves\\:\\ 0\\.06181246100116213\ \(0\)\
\-\ neoplasms\\:\\ 0\\.061682811055797204\ \(0\)\
\-\ neoplastic\\:\\ 0\\.06117822941157638\ \(0\)\
\-\ 47\\:\\ 0\\.06069467822058364\ \(0\)\
\-\ prevent\\:\\ 0\\.06069467822058364\ \(0\)\
\-\ on\\:\\ 0\\.05997233459697472\ \(0\)\
\-\ replacement\\:\\ 0\\.05946028795352295\ \(0\)\
\-\ lead\\:\\ 0\\.05893986219375237\ \(0\)\
\-\ systemic\\:\\ 0\\.05873805624817767\ \(0\)\
\-\ unlikely\\:\\ 0\\.058638454354284095\ \(0\)\
\-\ problems\\:\\ 0\\.057415898406854286\ \(0\)\
\-\ schwannoma\\:\\ 0\\.0567229433173259\ \(0\)\
\-\ occipital\\:\\ 0\\.05663916281334116\ \(0\)\
\-\ lack\\:\\ 0\\.05663916281334116\ \(0\)\
\-\ nodes\\:\\ 0\\.05622910072930176\ \(0\)\
\-\ dermoid\\:\\ 0\\.055911175379012655\ \(0\)\
\-\ report\\:\\ 0\\.05575542069959531\ \(0\)\
\-\ gi\\:\\ 0\\.055601729056789735\ \(0\)\
\-\ marrow\\:\\ 0\\.05500654478187195\ \(0\)\
\-\ complaints\\:\\ 0\\.05450968082958331\ \(0\)\
\-\ continued\\:\\ 0\\.0542350277849803\ \(0\)\
\-\ children\\:\\ 0\\.0542350277849803\ \(0\)\
\-\ cranial\\:\\ 0\\.054100101271768834\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.05351162619009506\ \(0\)\
\-\ from\\:\\ 0\\.0525764129128484\ \(0\)\
\-\ considered\\:\\ 0\\.05157811119391241\ \(0\)\
\-\ lymph\\:\\ 0\\.051470670154146\ \(0\)\
\-\ fibrous\\:\\ 0\\.051417320407788264\ \(0\)\
\-\ transverse\\:\\ 0\\.0509991292247115\ \(0\)\
\-\ cysts\\:\\ 0\\.050157565048720265\ \(0\)\
\-\ specific\\:\\ 0\\.050157565048720265\ \(0\)\
\-\ 18\\:\\ 0\\.050157565048720265\ \(0\)\
\-\ in\\:\\ 0\\.049398419166967696\ \(0\)\
\-\ skin\\:\\ 0\\.04923981028758573\ \(0\)\
\-\ developed\\:\\ 0\\.049108199620791264\ \(0\)\
\-\ ago\\:\\ 0\\.04843042745706963\ \(0\)\
\-\ abnormality\\:\\ 0\\.04814591286810805\ \(0\)\
\-\ could\\:\\ 0\\.04814591286810805\ \(0\)\
\-\ breast\\:\\ 0\\.04806588807235861\ \(0\)\
\-\ diagnosed\\:\\ 0\\.04794687626607688\ \(0\)\
\-\ presence\\:\\ 0\\.04755876151105505\ \(0\)\
\-\ ap\\:\\ 0\\.04752065458225014\ \(0\)\
\-\ did\\:\\ 0\\.04748267238993284\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.04699989510425885\ \(0\)\
\-\ wbc\\:\\ 0\\.04678367364188033\ \(0\)\
\-\ biopsy\\:\\ 0\\.04639743815634067\ \(0\)\
\-\ complete\\:\\ 0\\.04639743815634067\ \(0\)\
\-\ weight\\:\\ 0\\.04615818123885048\ \(0\)\
\-\ or\\:\\ 0\\.04605324851882009\ \(0\)\
\-\ enlarged\\:\\ 0\\.04512319593462138\ \(0\)\
\-\ masses\\:\\ 0\\.04506147478169063\ \(0\)\
\-\ radiation\\:\\ 0\\.04386356791287091\ \(0\)\
\-\ vascular\\:\\ 0\\.043698193863448254\ \(0\)\
\-\ past\\:\\ 0\\.04308523474948059\ \(0\)\
\-\ no\\:\\ 0\\.04304903402838569\ \(0\)\
\-\ differential\\:\\ 0\\.043007618745088565\ \(0\)\
\-\ will\\:\\ 0\\.04260221334044855\ \(0\)\
\-\ renal\\:\\ 0\\.04121892371786216\ \(0\)\
\-\ loss\\:\\ 0\\.040325902475759165\ \(0\)\
\-\ lung\\:\\ 0\\.04026466988304374\ \(0\)\
\-\ for\\:\\ 0\\.040123888023429775\ \(0\)\
\-\ likely\\:\\ 0\\.03955402645260186\ \(0\)\
\-\ head\\:\\ 0\\.039477687036515455\ \(0\)\
\-\ edema\\:\\ 0\\.039477687036515455\ \(0\)\
\-\ all\\:\\ 0\\.039401846574425116\ \(0\)\
\-\ he\\:\\ 0\\.0391958055784195\ \(0\)\
\-\ 10\\:\\ 0\\.038705057682877304\ \(0\)\
\-\ presented\\:\\ 0\\.03859876488410854\ \(0\)\
\-\ axial\\:\\ 0\\.03823422549939752\ \(0\)\
\-\ enhancement\\:\\ 0\\.038098311214683114\ \(0\)\
\-\ due\\:\\ 0\\.038047751006617274\ \(0\)\
\-\ therapy\\:\\ 0\\.03803094644264865\ \(0\)\
\-\ common\\:\\ 0\\.03753780355911366\ \(0\)\
\-\ over\\:\\ 0\\.03680503250086976\ \(0\)\
\-\ metastatic\\:\\ 0\\.036302379798452446\ \(0\)\
\-\ bone\\:\\ 0\\.036115800463638055\ \(0\)\
\-\ consistent\\:\\ 0\\.03589020795075457\ \(0\)\
\-\ follow\\:\\ 0\\.035682625502562876\ \(0\)\
\-\ bilateral\\:\\ 0\\.03557341481975623\ \(0\)\
\-\ can\\:\\ 0\\.03473487043542609\ \(0\)\
\-\ tumor\\:\\ 0\\.034621664177568005\ \(0\)\
\-\ most\\:\\ 0\\.03444773191506348\ \(0\)\
\-\ other\\:\\ 0\\.03437398029352285\ \(0\)\
\-\ it\\:\\ 0\\.03388218004456801\ \(0\)\
\-\ may\\:\\ 0\\.033309331771527395\ \(0\)\
\-\ up\\:\\ 0\\.03274212809707963\ \(0\)\
\-\ but\\:\\ 0\\.032731487519174644\ \(0\)\
\-\ female\\:\\ 0\\.03194014659745175\ \(0\)\
\-\ by\\:\\ 0\\.028108481331171706\ \(0\)\
\-\ normal\\:\\ 0\\.02702528746146596\ \(0\)\
\-\ not\\:\\ 0\\.026130580059582003\ \(0\)\
\-\ ct\\:\\ 0\\.025199484793429476\ \(0\)\
\-\ left\\:\\ 0\\.022579148601814616\ \(0\)\
\-\ right\\:\\ 0\\.02194501135117927\ \(0\)\
\-\ is\\:\\ 0\\.018126818825896625\ \(0\)\
